Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIVOT-10
NCT03785925Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Apr 2019
- Primary completion
- Feb 2022
- Modality
- Cytokines & Interferons
- Countries
- 18
01
Overview
Phase 2, open-label, single-arm trial of bempegaldesleukin in urothelial carcinoma (UC), sponsored by Nektar Therapeutics. Primary endpoint: Objective Response Rate (ORR) by RECIST 1.1 Per Blinded Independent Central Review (BICR) in Patients Whose Tumors Have Low PD-L1 Expression up to 27 months. Started Apr 2019; status: completed.
02
Drugs
bempegaldesleukin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03785925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03785925.